Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8760843 | 0.87 | LSS (0.76) | LSS | |
| SCHEMBL8762179 | 0.84 | LSS (1.00) | LSS | |
| SCHEMBL8484785 | 0.83 | LSS (0.71) | LSS | |
| SCHEMBL8484786 | 0.83 | LSS (0.71) | LSS | |
| SCHEMBL8759845 | 0.82 | LSS (1.00) | LSS | |
| SCHEMBL8762503 | 0.82 | LSS (0.73) | LSS | |
| SCHEMBL4311426 | 0.82 | LSS (1.00) | LSS | |
| SCHEMBL8760862 | 0.82 | LSS (1.00) | LSS | |
| SCHEMBL8760860 | 0.81 | LSS (0.68) | LSS | |
| SCHEMBL8760699 | 0.81 | LSS (1.00) | LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9176123-A | — | — | None | — | — | JP | disclosed |
| EP-2866810-B9 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | UNIV MISSOURI (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20150366824-A1 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2015-12-24 | — | — | US | disclosed |
| US-20150366824-A1 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2015-12-24 | — | — | US | disclosed |
| JP-H09176123-A | AMINOALKYL-SUBSTITUTED BENZO-HETEROCYCLIC COMPOUND | F HOFFMANN LA ROCHE AG | 1997-07-08 | — | — | JP | disclosed |
| EP-0778271-A2 | Aminoalkyl-substituted benzo-heterocyclic compounds | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366824-A1 | INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER | ESRRA, ESRRB, ESRRG | LSS 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.